The impact of different tumour subtypes on management and survival of New Zealand women with Stage I-III breast cancer

ResearchSpace/Manakin Repository

Show simple item record

dc.contributor.author Lawrenson, R en
dc.contributor.author Lao, C en
dc.contributor.author Campbell, Ian en
dc.contributor.author Harvey, V en
dc.contributor.author Seneviratne, S en
dc.contributor.author Elwood, James en
dc.contributor.author Sarfati, D en
dc.contributor.author Kuper-Hommel, M en
dc.date.accessioned 2018-10-12T00:56:38Z en
dc.date.issued 2018-05-18 en
dc.identifier.citation New Zealand medical journal 131(1475):51-60 18 May 2018 en
dc.identifier.issn 0028-8446 en
dc.identifier.uri http://hdl.handle.net/2292/41135 en
dc.description.abstract This study aims to describe the prevalence and characteristics of the different ER/PR/HER2 subtypes in New Zealand women with breast cancer, and to explore their treatment and outcomes.This study included women diagnosed with Stage I-III breast cancer between January 2006 and May 2013, recorded in the combined Waikato and Auckland Breast Cancer Registers, and with complete data on their ER, PR and HER2 status. Five ER/PR/HER2 phenotypes were classified. Kaplan-Meier method and Cox proportional hazards model were used to examine the survival differences among these subtypes.Of the 6,875 eligible women, 4,274 (62.2%) were classified as Luminal A, 836 (12.2%) as Luminal B HER2-, 605 (8.8%) as Luminal B HER2+, 401 (5.8%) as HER2+ non-Luminal and 759 (11.0%) as Triple Negative. Māori and Pacific women were less likely to have Triple Negative disease, while Pacific women were more likely to be HER2+ non-Luminal. The five-year breast cancer-specific survival was worst for HER2+ non-Luminal (80.1%) and Triple Negative (81.9%), followed by Luminal B HER2- (89.3%) and Luminal B HER2+ (91.6%), and was the best for Luminal A (96.8%). The adjusted breast cancer-specific mortality hazard ratio for Triple Negative and HER2+ non-Luminal compared to Luminal A was 4.91 (95% CI: 3.86-6.26) and 3.94 (95% CI: 2.94-5.30), respectively.The pattern of phenotype in women with Stage I-III breast cancer is similar to the overseas cohorts. Most New Zealand women with Luminal A breast cancer have a very good prognosis, but the less common subtypes have relatively poor outcomes. en
dc.format.medium Electronic en
dc.language eng en
dc.publisher New Zealand Medical Association en
dc.relation.ispartofseries New Zealand Medical Journal en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.rights.uri https://www.nzma.org.nz/journal/contribute/articles en
dc.title The impact of different tumour subtypes on management and survival of New Zealand women with Stage I-III breast cancer en
dc.type Journal Article en
pubs.issue 1475 en
pubs.begin-page 51 en
pubs.volume 131 en
dc.rights.holder Copyright: New Zealand Medical Association en
dc.identifier.pmid 29771902 en
pubs.author-url https://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2018/vol-131-no-1475-18-may-2018/7572 en
pubs.end-page 60 en
pubs.publication-status Published en
dc.rights.accessrights http://purl.org/eprint/accessRights/OpenAccess en
pubs.subtype Article en
pubs.elements-id 741827 en
pubs.org-id Medical and Health Sciences en
pubs.org-id Population Health en
pubs.org-id Epidemiology & Biostatistics en
pubs.org-id School of Medicine en
pubs.org-id Surgery Department en
dc.identifier.eissn 1175-8716 en
pubs.record-created-at-source-date 2019-03-01 en
pubs.dimensions-id 29771902 en


Full text options

Find Full text

This item appears in the following Collection(s)

Show simple item record

Share

Search ResearchSpace


Advanced Search

Browse